Concepedia

Norihisa Ohishi

NO

Statistics

Publications

12

Citations

432

H-Index

11

Active since

1983

Affiliations

Osaka City University(Current)

Chugai Pharma (United States)

Memorial Sloan Kettering Cancer Center

Norihisa Ohishi is an author at Osaka City University specializing in pharmacology, medicine, and cytochrome p450-mediated metabolism.

ORCID

Publications per year

1983–2018

12

Publications

12

First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma

Andrew X. Zhu, Philip J. Gold, Anthony B. El-Khoueiry et al. · Clinical Cancer Research · 2013 · 194 citations · Full text

, , +14

I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma

Jorge A. Carrasquillo, Joseph A. O’Donoghue, Volkan Beylergil et al. · EJNMMI Research · 2018 · 48 citations · Full text

, , +17

Characterization of two P-450 isozymes placed in the rat CYP2D subfamily

Norihisa Ohishi, Susumu Imaoka, Tokuji Suzuki et al. · Biochimica et Biophysica Acta (BBA) - General Subjects · 1993 · 28 citations

, , +7

Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)

Ghassan K. Abou‐Alfa, Chia-Jui Yen, Chih‐Hung Hsu et al. · Cancer Chemotherapy and Pharmacology · 2017 · 28 citations · Full text

, , +14

Pharmacokinetics and distribution of recombinant erythropoietin in rats.

H Kinoshita, Norihisa Ohishi, Motohiro Kato et al. · PubMed · 1992 · 27 citations

, , +7

1–5 of 12